America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)

WSW, NY, July 8th, 2026, FinanceWire

A new national study just put hard numbers on a treatment gap most Americans have never heard of. One microcap, Entera (NASDAQ: ENTX) has a proprietary oral peptide platform, an advancing pipeline, and a lead candidate that might close this exact gap

A slip on a wet floor. A stumble off a curb. For hundreds of thousands of American women each year, that's all it takes to break a wrist, crack a vertebra, or fracture a hip. Medically, that first fracture is supposed to trigger something: guidelines are clear that it should prompt evaluation and treatment for the underlying bone disease that likely caused it.

According to a national analysis released in June 2026 by Motive Medical Intelligence, built on more than 100 million U.S. insurance claims, that is not what's happening. In Rhode Island, the worst-performing state, 87% of women who suffered a fragility fracture received no osteoporosis treatment at all. Maine was close behind at 83%, followed by Connecticut at 81%, New Hampshire at 79%, and New York at 78%. This isn't a niche failure. It's a nationwide one. Zoom out and the scale gets even bigger: an estimated 200 million women worldwide live with osteoporosis, according to the International Osteoporosis Foundation. On that backdrop, Entera Bio (NASDAQ: ENTX), is a name becoming increasingly harder to ignore.

An Access Problem

The frustrating part is that effective medicine already exists. Anabolic therapies, the class of drugs that actively rebuild bone rather than just slowing its loss, have been available for over two decades. Eli Lilly's Forteo, the category's flagship, generated approximately $1.6 billion in annual sales in 2018, near its commercial peak before generic competition arrived. Major guideline bodies recommend anabolics as first-line therapy for high-risk patients.

The problem has never been whether these drugs work. It's how they're taken and who they are accessible to. Every approved anabolic on the market today is a subcutaneous injection, self-administered daily or dosed monthly in a clinic. In a disease that produces no symptoms until a bone breaks, asking a patient to inject themselves indefinitely is a hard sell, and the data on the resulting treatment gap, as the new Motive study shows, is stark.

Moreover, the needle is only part of the story. Access is the other half, and it starts with who is perscribing the anabolic treatments. Injectable anabolics have historically stayed within specialist care, while most osteoporosis diagnoses happen earlier, often during a routine visit with a gynecologist around menopause. In an April 2026 webinar Entera hosted with two leading clinicians, Dr. Steven Goldstein of NYU Grossman School of Medicine called an oral anabolic that the diagnosing physician could prescribe directly "access with a capital A."

The Company Developing the Pill That Might Close the Gap – EB613

Entera Bio (NASDAQ: ENTX) seems to be the only company developing an oral anabolic to close that gap by changing the format rather than the molecule. Its lead candidate, EB613, delivers PTH(1-34), the same active hormone in Forteo, as a once-daily oral tablet using the company's proprietary N-Tab platform.

The clinical case isn't speculative. A 161-patient, placebo-controlled Phase 2 trial, published in the Journal of Bone and Mineral Research, met its primary and secondary endpoints, producing statistically significant bone density gains at the spine, hip, and femoral neck. Just weeks ago, on June 22, 2026, Entera announced it had received positive FDA feedback on a streamlined, 750-patient Phase 3 protocol built around a 12-month bone density endpoint rather than a multi-year fracture trial, with the company targeting initiation in late 2026 and topline data in the second half of 2028.

Big Pharma Is Taking Bold Steps in the Sector

Here's the detail that may matter most for how this gets valued. In February 2026, Novo Nordisk agreed to pay MIT spinout Vivtex up to $2.1 billion for oral-peptide delivery technology alone, no drug asset attached, specifically a screening platform, using ex vivo gut tissue and machine learning to predict which formulations might carry a peptide across, not a therapy that has actually done so in a person yet.

Entera, in comparison, has a proprietary platform with human Phase 2 efficacy data behind its lead candidate, a Phase 3 protocol the FDA has responded to favorably, and three additional oral peptide programs, advancing through development: EB612 for hypoparathyroidism, EB618 for obesity and metabolic disease, and an oral GLP-2 tablet for short bowel syndrome. All of that currently sits inside a market capitalization of approximately $80 million as of early July 2026, elevated after the stock's move on the recent ENDO data and FDA feedback. Put another way, the amount Novo is committing to that platform alone is roughly 25 times Entera's entire current market value, while Entera has already carried its platform through human trials.

Small Cap, Hard-to-Ignore Setup

It's still early. Phase 3 trials fail even when earlier data looks strong, and drug development carries real risk. But the pieces here seem to line up. EB613's Phase 2 data held up across every key endpoint. The FDA's recent alignment on a streamlined Phase 3 design is a concrete, positive signal, not a hoped-for one. And the broader setup is hard to ignore: a newly quantified, worsening national treatment gap, a drug class that already works but that patients can’t fully access in its current form, and a technology in a field that Big Pharma has shown it will pay billions of dollars just to acquire. EB613, the rest of the pipeline, and the proprietary technology sit inside a company most investors have probably never heard of, already in human trials, at a fraction of the price. That gap, between what's already been de-risked and how the market is pricing it, looks like exactly the kind of mismatch that tends not to last.

Recent News Highlights from Entera (NASDAQ: ENTX)

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs 

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact